Shortening overall treatment to 12 weeks of SIMEPREVIR plus pegylated-interferon/ribavirin according to early virologic response in treatment-naïve patients with chronic HCV genot…
P Ferenci, T Asselah, C Moreno, A Craxi, F Sanai, R Ryan, O Lenz, G Van Dooren, I Lonjon-Domanec, M Schlag, M Buti · Zeitschrift für Gastroenterologie · 2015 · Heft 05
Bibliografische Angaben
Zusammenfassung
Aims: HCV genotype 4 (GT4) is highly prevalent in the Middle East and Sub-Saharan Africa, and is expanding in Europe. To prevent disease progression, short and effective regimens are needed for these patients. This study aims to assess whether treatment with simeprevir+Peg-IFN/ribavirin can be shortened to 12 weeks, based on early viral kinetics, in patients with mild-to-moderate fibrosis. Design: Phase-3, open-label study, including treatment-naïve patients in Europe and Saudi Arabia with HCV GT4. In patients with HCV-RNA < 25IU/mL (detectable/undetectable in IL28B CC, undetectable in CT/TT [Roche COBAS® Taqman…
